Focus on GABAA receptor function

SummaryImpairment of GABAA receptor function is increasingly recognized to play a major role in the pathophysiology of neuropsychiatric diseases including anxiety disorder (AD), major depressive disorder (MDD) and schizophrenia (SZ). Patients, method: We conducted a PUBMED search, which provided a total of 23 in vivo investigations with PET and SPECT, in which GABAA receptor binding in patients with the primary diagnosis of AD (n = 14, 160 patients, 172 controls), MDD (n = 2, 24 patients, 28 controls) or SZ (n = 6, 77 patients, 90 controls) was compared to healthy individuals. Results: A retrospective analysis revealed that AD, MDD and SZ differed as to both site(s) and extent(s) of GABAergic impairment. Additionally, it may be stated that, while the decline of GABAA receptor binding AD involved the whole mesolimbocortical system, in SZ it was confined to the frontal and temporal cortex. Conclusion: As GABA is known to inhibit dopamine and serotonin, GABAergic dysfunction may be associated with the disturbances of dopaminergic and serotonergic neurotransmission in neuropsychiatric disorders.

Download Full-text

Different patterns of 5-HT receptor and transporter dysfunction in neuropsychiatric disorders – a comparative analysis of in vivo imaging findings

Reviews in the Neurosciences ◽

10.1515/revneuro-2015-0014 ◽

2016 ◽

Vol 27 (1) ◽

pp. 27-59 ◽

Cited By ~ 12

Author(s):

Susanne Nikolaus ◽

Hans-Wilhelm Müller ◽

Hubertus Hautzel

Keyword(s):

Receptor Binding ◽

Binding Sites ◽

In Vivo Imaging ◽

Serotonin Receptor ◽

Primary Diagnosis ◽

Healthy Individuals ◽

Major Depressive ◽

Neuropsychiatric Diseases ◽

Pubmed Search

AbstractImpairment of serotonin receptor and transporter function is increasingly recognized to play a major role in the pathophysiology of neuropsychiatric diseases including anxiety disorder (AD), major depressive disorder (MDD), bipolar disorder (BD) and schizophrenia (SZ). We conducted a PubMed search, which provided a total of 136 in vivo studies with PET and SPECT, in which 5-HT synthesis, 5-HT transporter binding, 5-HT1 receptor binding or 5-HT2 receptor binding in patients with the primary diagnosis of acute AD, MDD, BD or SZ was compared to healthy individuals. A retrospective analysis revealed that AD, MDD, BD and SZ differed as to affected brain region(s), affected synaptic constituent(s) and extent as well as direction of dysfunction in terms of either sensitization or desensitization of transporter and receptor binding sites.

Download Full-text

Acute anxiety disorder, major depressive disorder, bipolar disorder and schizophrenia are related to different patterns of nigrostriatal and mesolimbic dopamine dysfunction

Reviews in the Neurosciences ◽

10.1515/revneuro-2018-0037 ◽

2019 ◽

Vol 30 (4) ◽

pp. 381-426 ◽

Cited By ~ 1

Author(s):

Susanne Nikolaus ◽

Eduards Mamlins ◽

Hubertus Hautzel ◽

Hans-Wilhelm Müller

Keyword(s):

Bipolar Disorder ◽

Major Depressive Disorder ◽

Anxiety Disorder ◽

Depressive Disorder ◽

Primary Diagnosis ◽

Emission Computed Tomography ◽

Major Depressive ◽

Neuropsychiatric Diseases ◽

Pubmed Search

AbstractDopamine (DA) receptor and transporter dysfunctions play a major role in the pathophysiology of neuropsychiatric diseases including anxiety disorder (AD), major depressive disorder (MDD), bipolar disorder (BD) in the manic (BDman) or depressive (BDdep) state and schizophrenia (SZ). We performed a PUBMED search, which provided a total of 239in vivoimaging studies with either positron emission tomography (PET) or single-proton emission computed tomography (SPECT). In these studies, DA transporter binding, D1receptor (R) binding, D2R binding, DA synthesis and/or DA release in patients with the primary diagnosis of acute AD (n=310), MDD (n=754), BDman(n=15), BDdep(n=49) or SZ (n=1532) were compared to healthy individuals. A retrospective analysis revealed that AD, MDD, BDman, BDdepand SZ differed as to affected brain region(s), affected synaptic constituent(s) and extent as well as direction of dysfunction in terms of either sensitization or desensitization of transporter and/or receptor binding sites. In contrast to AD and SZ, in MDD, BDmanand BDdep, neostriatal DA function was normal, whereas MDD, BDman, and BDdepwere characterized by the increased availability of prefrontal and frontal DA. In contrast to AD, MDD, BDmanand BDdep, DA function in SZ was impaired throughout the nigrostriatal and mesolimbocortical system with an increased availability of DA in the striatothalamocortical and a decreased availability in the mesolimbocortical pathway.

Download Full-text